📰 Time Dynamix News
Page 4 - Time Dynamix News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Time Dynamix. Real-time updates on events, politics, business and more.
January 13, 2022
/PRNewswire/ -- Impels new entrant into the acute migraine landscape, the dihydroergotamine mesylate (DHE) nasal spray, Trudhesa, is off to a somewhat light...
December 9, 2021
/PRNewswire/ -- In their most recent earnings call on October 29, 2021, Takeda revealed that discussions with the FDA have led to a potential approval for...
December 1, 2021
/PRNewswire/ -- For decades, nephrologists across the globe have prescribed erythropoietin stimulating agents (ESAs), such as Amgens Aranesp, Roches Mircera,...
December 1, 2021
/PRNewswire/ -- For decades, nephrologists across the globe have prescribed erythropoietin stimulating agents (ESAs), such as Amgens Aranesp, Roches Mircera,...
October 20, 2021
/PRNewswire/ -- Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibbs Zeposia and the May 2021 approval of Janssens...
October 20, 2021
/PRNewswire/ -- Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibbs Zeposia and the May 2021 approval of Janssens...
October 12, 2021
/PRNewswire/ -- Following the May 2021 FDA approval of Biohavens Nurtec ODT for the preventive treatment of episodic migraine, primary care physicians (PCPs)...
May 12, 2021
/PRNewswire/ -- Nephrologists have long considered chronic kidney disease (CKD) progression and diabetic kidney disease (DKD) as areas in dire need of new and...
March 4, 2021
Share this article Share this article EXTON, Pa., March 4, 2021 /PRNewswire/ -- Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with and without diabetes created a stir and caused optimism about potential paradigm shifts...
February 17, 2021
Share this article Share this article EXTON, Pa., Feb. 17, 2021 /PRNewswire/ -- Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis Cosentyx and Eli Lillys Taltz, have since experienced rapid uptake. According to feedback from 97 US rheumatologists in the latest report included in Spherixs RealTime Dynamix ™ service, the official entrance of the IL-17 inhibitors is causing a shift in the ...